Antibodies are essential in modern life sciences biotechnology. Their architecture and
diversity allow for high specificity and affinity to a wide array of biochemicals. Combining …

Chimeric antigen receptor T (CAR-T) cell therapy has produced impressive results in clinical
trials for B-cell malignancies. However, safety concerns related to the inability to control CAR …

Monoclonal antibodies (mAbs) are well established in the clinic due to their specificity and
affinity to a diverse array of biochemical targets. More recently, mAbs are being exploited as …

Highlights•A fraction of camelid and bovine antibodies possess a unique long CDR-H3
loop.•About 10 amino acids of the camel CDR-H3 protrudes from the paratope.•The 60–70 …

Antibodies provide a broad defense against a vast array of antigens; however, the structural
features that contribute to this diverse antigen recognition vary in different vertebrates. In …

Antidiabetic treatments aiming to reduce body weight are currently gaining increased
interest. Exendin-4, a glucagon-like peptide-1 (GLP-1) receptor agonist administered twice …

In contrast to other species, cattle possess exceptional antibodies with ultra-long
complementarity-determining regions (ulCDRs) that can consist of 40-70 amino acids. The …

Peptides and proteins are two classes of molecules with attractive possibilities for
therapeutic applications. However, the bottleneck for the therapeutic application of many …

Monoclonal antibodies (mAbs) exhibiting highly selective binding to a protein target
constitute a large and growing proportion of the therapeutics market. Aggregation of mAbs …

Cathepsin S (CTSS) is involved in pathogenesis of many human diseases. Inhibitors
blocking its protease activity hold therapeutic potential. In comparison to small-molecule …